Promising cancer drug trial pulled before it even started
NCT ID NCT06730100
First seen Nov 01, 2025 · Last updated Jun 23, 2026 · Updated 32 times
Summary
This phase 2 trial was designed to test CBX-12, a drug that delivers a cancer-killing substance directly to tumor cells, in people with metastatic colorectal cancer that had stopped responding to standard treatments. The study was withdrawn before any participants were enrolled, so no results are available. The goal was to see if CBX-12 could shrink tumors in this hard-to-treat group.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for STAGE IV COLORECTAL CANCER AJCC V8 are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Johns Hopkins University/Sidney Kimmel Cancer Center
Baltimore, Maryland, 21287, United States
-
M D Anderson Cancer Center
Houston, Texas, 77030, United States
-
Montefiore Medical Center-Einstein Campus
The Bronx, New York, 10461, United States
-
Northwestern University
Chicago, Illinois, 60611, United States
-
Ohio State University Comprehensive Cancer Center
Columbus, Ohio, 43210, United States
-
UC Irvine Health/Chao Family Comprehensive Cancer Center
Orange, California, 92868, United States
-
UCI Health - Chao Family Comprehensive Cancer Center and Ambulatory Care
Irvine, California, 92612, United States
-
USC / Norris Comprehensive Cancer Center
Los Angeles, California, 90033, United States
-
University of Cincinnati Cancer Center-UC Medical Center
Cincinnati, Ohio, 45219, United States
-
University of Cincinnati Cancer Center-West Chester
West Chester, Ohio, 45069, United States
-
University of Florida Health Science Center - Gainesville
Gainesville, Florida, 32610, United States
-
University of Pittsburgh Cancer Institute (UPCI)
Pittsburgh, Pennsylvania, 15232, United States
-
University of Virginia Cancer Center
Charlottesville, Virginia, 22908, United States
-
University of Wisconsin Carbone Cancer Center - Eastpark Medical Center
Madison, Wisconsin, 53718, United States
-
University of Wisconsin Carbone Cancer Center - University Hospital
Madison, Wisconsin, 53792, United States
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
CBX-12 (a drug that links a peptide to an anticancer substance called exatecan)
What this could lead to
If it worked, CBX-12 could offer a new treatment option for patients with advanced colorectal cancer that no longer responds to standard therapies.
What could go wrong
This trial was withdrawn before enrolling any participants, so no data on safety or effectiveness were collected. The drug is still early in testing and may not work or may cause side effects.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.